检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:谢军平(综述)[1] 侯晓华[1] 陶晓南(审校)[1]
机构地区:[1]华中科技大学同济医学院附属协和医院,武汉430022
出 处:《国际肿瘤学杂志》2008年第9期664-667,共4页Journal of International Oncology
摘 要:树突状细胞(DC)是诱导初始免疫应答反应的专职抗原提呈细胞,它能捕获抗原并加工处理成小分子多肽,通过MHCⅠ类和Ⅱ类分子提呈给T细胞和B细胞。DC与肿瘤细胞融合所获得的融合瘤细胞,在共刺激信号存在的条件下,能够加工处理细胞内许多已知和未知的肿瘤相关抗原(TAA),并通过MHCⅠ类和Ⅱ类分子提呈。目前,DC融合瘤苗在动物和临床研究中取得了许多进展,已成为肿瘤免疫治疗的热点之一。Dendritic cells (DCs) are potent professional antigen-presenting cells which are able to in- duce primary immune responses. DC can capture and process antigens into small-molecule peptides and present them to T cells and B cells through MHC class Ⅰ and Ⅱ molecules. An alternative approach to the induction of antitumor immunity is the use of fusion of DC and tumor cells. In this approach, a broad spectrum of known and unknown tumor-associated antigens (TAA) are presented by MHC class Ⅰ and Ⅱ molecules. In animal and clinical studies, dendritic/tumor fusion ceil-based vaccine has made much progress and become a focus of the tumor immunotherapy.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.171